参附注射液联合沙库巴曲缬沙坦钠治疗顽固性心力衰竭的疗效  

Efficacy of Shenfu injection combined with sacurabatril valsartan sodium in treating patients with refractory heart failure

作　　者：曹俊达 刘秋连[1] 袁向阳[1] 户洁 韩业婷 曹原[1] 王琦[1] CAO Junda;LIU Qiulian;YUAN Xiangyang(Department of Cardiology,Jiujiang First People’s Hospital,Jiujiang 332000,CHINA)

机构地区：[1]九江市第一人民医院心内科,江西332000

出　　处：《江苏医药》2020年第7期701-705,共5页Jiangsu Medical Journal

摘　　要：目的观察参附注射液联合沙库巴曲缬沙坦钠治疗顽固性心力衰竭患者的临床疗效。方法53例顽固性心力衰竭患者随机分为观察组(27例)和对照组(26例)。对照组给予沙库巴曲缬沙坦钠、利尿、β受体阻滞剂、强心等规范化的心力衰竭治疗;观察组在此基础上增加参附注射液60 mL/d静脉滴注,连续使用14 d。记录两组患者沙库巴曲缬沙坦钠日用总量,观察心功能指标变化,检测血浆N末端B型利钠肽原(NT-proBNP)、超敏CRP(hs-CRP)和IL-6水平,比较临床疗效。结果观察组沙库巴曲缬沙坦钠日用总量大于对照组[(170.85±45.34)mg vs.(120.23±40.21)mg](P<0.05)。观察组的总有效率为88.89%,高于对照组的73.08%(P<0.01)。治疗后,观察组的左室射血分数、左心室舒张末期内径、每搏输出量的改善均优于对照组(P<0.05),观察组血浆hs-CRP和IL-6低于对照组(P<0.05)。结论在规范心力衰竭治疗基础上,加用参附注射液能进一步改善顽固性心力衰竭患者的心功能,降低神经内分泌和炎性因子水平。Objective To observe the clinical efficacy of Shenfu injection combined with sacurabatril valsartan sodium in the treatment of the patients with refractory heart failure.MethodsFifty-three patients with refractory heart failure were randomly assigned into two groups.The patients in group B(26 cases)were treated with standardized treatments including sacubatril valsartan sodium,diuresis,β-blockers,and cardiotonic.The patients in group A(27 cases)were treated additionally with intravenous infusion of Shenfu injection 60 mL once a day for 14 days.The consumption of sacubatril valsartan sodium was recorded,the changes of cardiac function indicators were observed,plasma levels of N-terminal pro-B-type natriuretic peptide(NT-proBNP),hypersensitive CRP(hs-CRP)and IL-6 were detected before and after treatment,and the clinical efficacy of treatment was compared between the two groups.Results The daily used dose of sacubatril valsartan sodium was more in group A than that in group B[(170.85±45.34)mg vs.(120.23±40.21)mg](P<0.05).The total effective rate of treatment was higher in group A than that in group B(88.89%vs.73.08%)(P<0.01).The improvements in the left ventricular ejection fraction,left ventricular end diastolic diameter,stroke volume,and NT-proBNP after treatment were all better in group A than those in group B(P<0.05).levels of hs-CRP and IL-6 after treatment were better in group A than those in group B(P<0.05).Conclusion On the basis of standardized treatment,combined use of Shenfu injection can further improve the heart function and reduce plasma levels of neuroendocrine and inflammatory factors in the patients with refractory heart failure.

关 键 词：参附注射液 沙库巴曲缬沙坦钠 顽固性心力衰竭 

分 类 号：R541[医药卫生—心血管疾病]